Skip to main content
Top
Published in: Lung 3/2013

01-06-2013

Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines

Authors: Angelika Reissig, Christine Mempel, Ulrike Schumacher, Roberto Copetti, Florian Gross, Stefano Aliberti

Published in: Lung | Issue 3/2013

Login to get access

Abstract

Background

The aim of this secondary analysis was to evaluate current microbiological approaches, microbiology, and antibiotic therapy in patients with community-acquired pneumonia (CAP) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in clinical practice and to compare them with current international guidelines.

Methods

A total of 362 patients with suspected CAP were enrolled in 14 European centers in a prospective multicenter study.

Results

A total of 279 inpatients (CAP, n = 222; AECOPD, n = 57) were evaluated. A total of 83 (37 %) CAP patients and 25 (44 %) AECOPD patients did not undergo any microbiological tests. In patients with CAP/AECOPD, blood culture was performed in 109 (49 %)/16 (28.1 %), urinary antigen tests for Legionella pneumophila in 67 (30 %)/9 (16 %), and sputum investigation in 55 (25 %)/17 (30 %), respectively. The most frequent pathogens in CAP were Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, L. pneumophila, Staphylococcus aureus, and Enterobacter cloacae; in AECOPD they were Escherichia coli, Haemophilus haemolyticus, Haemophilus influenzae, and Moraxella catarrhalis. All CAP patients (mean = 11.1 days) and 35 (61.4 %) of AECOPD patients (mean = 8.9 days) received antibiotics. CAP patients were given mostly aminopenicillin with β-lactamase inhibitors and AECOPD patients were given mostly cephalosporins.

Conclusions

Pathogens isolated in CAP and AECOPD and the antibiotic therapy used are in good accordance with the guidelines. Blood culture, recommended for all CAP patients, was performed in only 50 % of the cases and antibiotic therapy lasted longer than the suggested 5–7 days. Therefore, international guidelines regarding performance of blood culture and duration of antibiotic therapy should be adopted more often. This duration was independent of the number of isolated pathogens and number of symptoms on admission. Therefore, the question arises as to whether microbiological data are necessary only for patients who are resistant to initial therapy.
Literature
1.
go back to reference Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M et al (2011) Joint task force of the European respiratory society and European society for clinical microbiology and infectious diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 17(Suppl 6):1–59PubMedCrossRef Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M et al (2011) Joint task force of the European respiratory society and European society for clinical microbiology and infectious diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 17(Suppl 6):1–59PubMedCrossRef
2.
go back to reference Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K et al (2009) Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the competence network CAPNETZ Germany. Pneumologie 63:e1–e68PubMedCrossRef Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K et al (2009) Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the competence network CAPNETZ Germany. Pneumologie 63:e1–e68PubMedCrossRef
3.
go back to reference Global strategy for the diagnosis, management, and prevention of chronic obstuctive pulmonary disease. www.goldcopd.org. Accessed Feb 2013 Global strategy for the diagnosis, management, and prevention of chronic obstuctive pulmonary disease. www.​goldcopd.​org. Accessed Feb 2013
4.
go back to reference Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I et al (2009) Pneumonia guidelines committee of the BTS standards of care committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 64(Suppl 3):1–55CrossRef Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I et al (2009) Pneumonia guidelines committee of the BTS standards of care committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 64(Suppl 3):1–55CrossRef
5.
go back to reference National Institute for Health and Care Excellence, National Clinical Guideline Centre, Chronic Obstructive Pulmonary Disease (2010) Management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101). http://guidance.nice.org.uk/CG101 National Institute for Health and Care Excellence, National Clinical Guideline Centre, Chronic Obstructive Pulmonary Disease (2010) Management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101). http://​guidance.​nice.​org.​uk/​CG101
6.
go back to reference Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious diseases society of America; American thoracic society (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72PubMedCrossRef Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious diseases society of America; American thoracic society (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72PubMedCrossRef
7.
go back to reference Celli BR, MacNee W, ATS/ERS Task Force (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 23:932–946 Celli BR, MacNee W, ATS/ERS Task Force (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 23:932–946
8.
go back to reference Reissig A, Copetti R, Mathis G, Mempel C, Schuler A, Zechner P et al (2012) Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. A prospective multicentre diagnostic accuracy study. Chest 142:965–972PubMedCrossRef Reissig A, Copetti R, Mathis G, Mempel C, Schuler A, Zechner P et al (2012) Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. A prospective multicentre diagnostic accuracy study. Chest 142:965–972PubMedCrossRef
9.
go back to reference National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing, 14th informational supplement. Approved standard M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing, 14th informational supplement. Approved standard M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards
10.
go back to reference Herrero FS, Olivas JB (2012) Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 33:220–231CrossRef Herrero FS, Olivas JB (2012) Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 33:220–231CrossRef
11.
go back to reference Welte T, Köhnlein T (2009) Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med 30:127–135PubMedCrossRef Welte T, Köhnlein T (2009) Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med 30:127–135PubMedCrossRef
12.
go back to reference Pletz MW, Rohde G, Schütte H, Bals R, von Baum H, Welte T (2011) Epidemiology and aetiology of community-acquired Pneumonia (CAP). Dtsch Med Wochenschr 136:775–780PubMedCrossRef Pletz MW, Rohde G, Schütte H, Bals R, von Baum H, Welte T (2011) Epidemiology and aetiology of community-acquired Pneumonia (CAP). Dtsch Med Wochenschr 136:775–780PubMedCrossRef
13.
go back to reference Echols RM, Tillotson GS, Song JX, Tosiello RL (2008) Clinical trial design for mild-to-moderate community-acquired pneumonia—an industry perspective. Clin Infect Dis 47(Suppl 3):S166–S175PubMedCrossRef Echols RM, Tillotson GS, Song JX, Tosiello RL (2008) Clinical trial design for mild-to-moderate community-acquired pneumonia—an industry perspective. Clin Infect Dis 47(Suppl 3):S166–S175PubMedCrossRef
14.
go back to reference Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S (2010) Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J 36:128–134PubMedCrossRef Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S (2010) Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J 36:128–134PubMedCrossRef
15.
go back to reference Li JZ, Winston LG, Moore DH et al (2007) Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a metaanalysis. Am J Med 120:783–790PubMedCrossRef Li JZ, Winston LG, Moore DH et al (2007) Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a metaanalysis. Am J Med 120:783–790PubMedCrossRef
Metadata
Title
Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines
Authors
Angelika Reissig
Christine Mempel
Ulrike Schumacher
Roberto Copetti
Florian Gross
Stefano Aliberti
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Lung / Issue 3/2013
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9460-x

Other articles of this Issue 3/2013

Lung 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.